Skip to main
TYRA
TYRA logo

Tyra Biosciences (TYRA) Stock Forecast & Price Target

Tyra Biosciences (TYRA) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tyra Biosciences is poised for significant advancements in its product pipeline, particularly with the potential of TYRA-300 to improve clinical outcomes such as annual height velocity and associated clinical sequelae. The company's strategic emphasis on multiple indications for TYRA-300, along with the initiation of trials for lower doses across varied patient cohorts, underscores a proactive development approach as it anticipates a busy 2025. Furthermore, Tyra's innovative SNAP platform enhances its drug design capabilities, positioning the company to effectively target large opportunities in FGFR biology and strengthen its competitive standing in the biotechnology sector.

Bears say

Tyra Biosciences reported a substantial net loss of $25.6 million, translating to a loss of $0.43 per share, which aligns closely with existing estimates. The company faces significant challenges in its product development pipeline, particularly concerning the safety profiles of its drug candidates compared to existing FGFR inhibitors, which exhibit high toxicity rates and adverse effects. Additionally, there are critical risks associated with clinical or regulatory setbacks for TYRA-300 that could hinder its ability to meet revenue expectations if approved, further contributing to a negative outlook on the stock.

Tyra Biosciences (TYRA) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tyra Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tyra Biosciences (TYRA) Forecast

Analysts have given Tyra Biosciences (TYRA) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Tyra Biosciences (TYRA) has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tyra Biosciences (TYRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.